OncRef

Clinical Trial: NCT02500407

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Genentech, Inc.
Information Provided By:Genentech, Inc.
Last Update Posted:2025-09-12

Study Overview

Brief Summary

This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Official Title

An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Conditions

Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin

Intervention / Treatment

  • Drug: BTCT4465A (Mosunetuzumab) IV
  • Drug: Atezolizumab
  • Drug: BTCT4465A (Mosunetuzumab) SC

Other Study ID Numbers

  • GO29781

Start Date (Actual)

2015-09-15

Primary Completion Date (Actual)

2024-05-21

Study Completion Date (Actual)

2025-09-01

Enrollment (Actual)

713

Study Type

Interventional

Phase

Phase 1, Phase 2